Acorda Therapeutics, Inc. (NASDAQ:ACOR)
CAPS Rating:
A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.
RSS Headlines
Fool UK
Recs
FDA approval seems likely.